ANAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ANAB is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has a constructive technical setup, a favorable proprietary SwingMax signal, and multiple analyst firms have recently raised price targets while maintaining bullish ratings. The current price is also sitting near support rather than extended far above it. Given the lack of recent negative news and the upcoming GSK dispute court date as a possible catalyst, the risk/reward looks attractive for a long-term entry, and the current price does not require waiting for a better setup.
ANAB's trend is currently bullish. MACD histogram is positive at 1.135, showing upward momentum even though it is contracting slightly. RSI_6 at 57.095 is neutral-to-bullish, not overbought. The moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which supports an established uptrend. Price at 63.34 is above the pivot of 62.162 and below first resistance at 67.552, so the stock is trading in a favorable zone with room toward resistance. The stock trend model also points to modest upside over the next week and month.
["Leerink raised price target to $90 and kept Outperform ahead of the July 14-17 GSK dispute court date.", "UBS raised price target to $76 and kept Buy.", "Barclays raised price target to $75 and kept Overweight after Q1.", "Piper Sandler remains Overweight and views the royalty business separation as value-enhancing.", "Upcoming court date related to the GSK dispute could create a material positive catalyst if resolved favorably.", "SwingMax issued an entry signal on 2026-06-15, and the stock is already up 9.26% since then, confirming that the move has had follow-through."]
["Regular market session was down 3.07%, showing some short-term selling pressure.", "Put open interest exceeds call open interest, signaling cautious hedging sentiment.", "Q1 Jemperli collaboration revenue was below expectations according to Leerink.", "No recent news in the last week, so there is no fresh near-term headline support.", "Hedge funds and insiders are both neutral, with no significant buying trend."]
No detailed latest-quarter financial statement data was provided, so I cannot assess revenue, EPS, or margin trends directly. The only financial-related note available is that Q1 Jemperli collaboration revenue came in below expectations, but analysts still raised targets because they expect the royalty business to improve and because AnaptysBio now operates as a more focused royalty management company after the TRAX spin-off. The latest referenced quarter in the analyst commentary is Q1 2026.
Analyst sentiment is positive and improving. Over the past few weeks, multiple firms raised price targets: Leerink to $90 from $85 with Outperform, UBS to $76 from $60 with Buy, Barclays to $75 from $63 with Overweight, and Piper Sandler to $93 from $95 while keeping Overweight. The tone from Wall Street is constructive, with the main bull case centered on royalty value, Jemperli cash flows, and upside from the GSK dispute. The bearish side is limited to the fact that some revenue came in below expectations and UBS/Barclays had previously cut targets before recent rebound upgrades, but overall the pros currently outweigh the cons.
